

## References

### I-9

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Zimran A, Gonzalez-Rodriguez D, Abrahamov A, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. *Blood Cells Mol Dis*. 2015;54(1):9-16.
3. Abbas R, Park G, Damle B, et al. Pharmacokinetics of Novel Plant CellExpressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher PLoS One. 2015;8;10(6).
4. Hughes D, Gonzalez D, Lukina A, et Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. *Am J Hematol*. 2015;90(7):584-91.
5. Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, et Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase. *Blood Cells Mol Dis*. 2016.
6. Serratrice C, Carballo S, Serratrice J and Stirnemann Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. *Core Evid*. 2016;11:37-4.
7. Elstein D, Burrow TA, Charrow J, et al. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher *Mol Genet Metab*.2016;1-5.
8. Elstein D, Abrahamov A, Oz A, et 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease. *Bld Cell Mol Dis*. 2015;415- 418.
9. Polinski JM, Kowal MK, Gagnon M, et Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016. Accessed November 9, 2017.
10. ASHP Guidelines on Home Infusion Pharmacy Services, Accessed September 2, 2017.
11. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
12. MICROMEDEX®SOLUTIONS 2020. Imiglucerase.
13. MICROMEDEX®SOLUTIONS 2020. Velaglucerase Alfa.
14. Micromedex®Solutions Compendia. 2020. Taliglucerase alfa.

15. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Imiglucerase. 2020.
16. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Taliglucerase Alfa. 2020.
17. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Velaglucerase Alfa. 2020.
18. Stirnemann J, Belmatoug N, Camou F, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. *International Journal of Molecular Sciences*. 2017;18(2):441.
19. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. *Expert Rev Endocrinol Metab*. 2018;13(2):107-
20. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. *Molecular Genetics and Metabolism*. 2017;120(1-2):47-56.
21. Pastores GM, Hughes DA. Gaucher disease. *GeneReviews*. 2018;1-35.
22. Cerezyme (imiglucerase) for injection [package insert]. Genzyme Corporation. Cambridge, MA. Revised 04/2018
23. Elelyso (taliglucerase alfa) for injection, for intravenous use [package insert]. Pfizer Labs. New York, New York. Revised 10/2019.
24. VPRIV (velaglucerase alfa) for injection, for intravenous use [package insert]. Shire Human Genetic Therapies, Inc. Lexington, MA. Revised 11/2019.
25. National Institute of Health. National Organization for Rare Disorders. Gaucher Disease. Last published: 2018.